{
    "Trade/Device Name(s)": [
        "CAPILLARYS Hb A1c"
    ],
    "Submitter Information": "Sebia, Inc.",
    "510(k) Number": "K171861",
    "Predicate Device Reference 510(k) Number(s)": [
        "K131580"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PDJ"
    ],
    "Summary Letter Date": "December 14, 2017",
    "Summary Letter Received Date": "December 20, 2017",
    "Submission Date": "February 6, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.1373"
    ],
    "Regulation Name(s)": [
        "Hemoglobin A1c test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c"
    ],
    "Specimen Type(s)": [
        "Venous whole human blood",
        "Whole blood"
    ],
    "Specimen Container(s)": [
        "Tube"
    ],
    "Instrument(s)/Platform(s)": [
        "CAPILLARYS 2 FLEX-PIERCING instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Capillary electrophoresis"
    ],
    "Methodologies": [
        "Quantitative measurement",
        "Separation and quantification of HbA1c fraction"
    ],
    "Submission Type(s)": [
        "Kit",
        "Calibrator",
        "Control",
        "Analyzer",
        "Reagent",
        "Software",
        "Instrument"
    ],
    "Document Summary": "FDA 510(k) summary for CAPILLARYS Hb A1c capillary electrophoresis assay for HbA1c quantification using the CAPILLARYS 2 FLEX-PIERCING instrument",
    "Indications for Use Summary": "Intended for separation and quantification of the HbA1c glycated fraction in venous whole human blood as an aid in diagnosis of diabetes, identification of patients at risk for diabetes, and monitoring of long-term blood glucose control in individuals with diabetes mellitus",
    "fda_folder": "Clinical Chemistry"
}